The First I.M. Sechenov Moscow State Medical University (Sechenov University), Moscow, Russian Federation.
Moscow City Clinical Hospital No. 52, Moscow, Russian Federation.
Int Arch Allergy Immunol. 2021;182(8):765-774. doi: 10.1159/000515253. Epub 2021 May 19.
The aim of this study is to evaluate the frequency of cardiac involvement in patients with coronavirus disease 2019 (COVID-19), possible immune mechanisms of myocardial injury, and the place of cardiovascular pathology among other prognostic factors.
The study included 86 patients (48 male, 60.2 ± 16.6 years) with COVID-19. In addition to common investigation, examination of troponin T (n = 18) and anti-heart antibodies (AHA, n = 34) were used. The average hospital period was 14 [12; 18] days.
The incidence of cardiovascular disease and symptoms was 45.3%. Arrhythmias, heart failure, low-QRS voltage, repolarization disorders, and pericardial effusion were the typical for coronavirus cardiac injury. The level of AHA was increased in 73.5%. Significant (p < 0.05) correlations of AHA level with inflammatory activity, pneumonia, respiratory failure, cardiac symptoms, and death were found. D-dimer >0.5 μg/mL had a sensitivity of 79.2% and specificity of 60% in the prediction of cardiovascular manifestations. Cardiac failure was one of the causes of death in 3/8 patients (37.5%). Lethality in the presence of cardiovascular pathology was 17.9 versus 2.2% without it, p < 0.05. The most powerful prognostic model includes age, diabetes, oxygen therapy volume, maximum leukocyte level, C-reactive protein, and D-dimer (correlation coefficient 0.871, p < 0.001). The model with only age, diabetes, and cardiovascular disease included also had predictive power (correlation coefficient 0.568, p < 0.001).
The cardiovascular pathology is frequent in patients with COVID-19 and strong correlates with the D-dimer. It indicates the high significance of prothrombotic and ischemic mechanisms. High AHA levels may reflect an inflammatory heart injury. The cardiovascular pathology is associated with higher lethality.
本研究旨在评估 2019 年冠状病毒病(COVID-19)患者心脏受累的频率、心肌损伤的可能免疫机制以及心血管病理学在其他预后因素中的地位。
本研究纳入了 86 例 COVID-19 患者(48 名男性,60.2±16.6 岁)。除了常规检查外,还检测了肌钙蛋白 T(n=18)和抗心肌抗体(AHA,n=34)。平均住院时间为 14[12;18]天。
心血管疾病和症状的发生率为 45.3%。心律失常、心力衰竭、低 QRS 波电压、复极障碍和心包积液是冠状病毒性心脏损伤的典型表现。73.5%的患者 AHA 水平升高。AHA 水平与炎症活动、肺炎、呼吸衰竭、心脏症状和死亡均呈显著相关(p<0.05)。D-二聚体>0.5μg/mL 对心血管表现的预测具有 79.2%的敏感性和 60%的特异性。心力衰竭是 8 例患者死亡的原因之一(37.5%)。存在心血管疾病时的死亡率为 17.9%,而不存在时为 2.2%,p<0.05。最强大的预后模型包括年龄、糖尿病、氧疗量、白细胞最高值、C 反应蛋白和 D-二聚体(相关系数 0.871,p<0.001)。仅包含年龄、糖尿病和心血管疾病的模型也具有预测能力(相关系数 0.568,p<0.001)。
COVID-19 患者中常发生心血管疾病,与 D-二聚体密切相关。这表明存在高凝和缺血性机制。高 AHA 水平可能反映炎症性心脏损伤。心血管疾病与更高的死亡率相关。